JMAC ENTERPRISES LLC - BRAINSTORM CELL THERAPEUTICS ownership

BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 49 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q2 2022. The put-call ratio across all filers is 0.17 and the average weighting 0.0%.

Quarter-by-quarter ownership
JMAC ENTERPRISES LLC ownership history of BRAINSTORM CELL THERAPEUTICS
ValueSharesWeighting
Q3 2023$13,093
-84.3%
65,430
+61.8%
0.00%
-85.7%
Q2 2023$83,286
-37.6%
40,4300.0%0.02%
-38.2%
Q1 2023$133,419
+101.2%
40,4300.0%0.03%
+88.9%
Q4 2022$66,305
-63.0%
40,4300.0%0.02%
-64.0%
Q3 2022$179,000
+43.2%
40,430
-11.0%
0.05%
+56.2%
Q2 2022$125,000
-18.3%
45,4300.0%0.03%
-11.1%
Q1 2022$153,00045,4300.04%
Other shareholders
BRAINSTORM CELL THERAPEUTICS shareholders Q2 2022
NameSharesValueWeighting ↓
Ikarian Capital, LLC 189,935$311,4940.08%
ABNER HERRMAN & BROCK LLC 280,000$4590.07%
Weaver Consulting Group 65,947$108,1530.06%
S.C. Financial Services, Inc. 25,372$41,6100.03%
JMAC ENTERPRISES LLC 40,430$66,3050.02%
Weaver Consulting Group 53,500$10,0470.01%
IFP Advisors, Inc 26,650$1390.00%
Bangor Savings Bank 4,000$70.00%
INSTITUTIONAL & FAMILY ASSET MANAGEMENT, LLC 3,000$4,9200.00%
BOOTHBAY FUND MANAGEMENT, LLC 19,098$31,3210.00%
View complete list of BRAINSTORM CELL THERAPEUTICS shareholders